So what is everyone’s opinion? In my view Nirma has no expertise in running a pharma business. While Sakhmet is just a PE firm. Is long term investing justified in GLS? Please share your views.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
